Skip to main content

Errata - English

PDF CSV May 15, 2022 through May 15, 2024 All Errata for USP–NF How to use
Enter the title of the monograph
Monograph Title Section Source Publication Sort descending Page Number Errata Official Date Target Errata Print Publication Target Online Fix Publication Description
CALCIUM SULFATE ASSAY/Procedure USP35–NF30 1724 1-Oct-2012 USP37–NF32 First Supplement to USP36–NF31 Line 5 of Titrimetric system: Delete the subsection
Blank: 100 mL of water and 4 mL of 3 N hydrochloric acid
AND
Line 11 of Analysis: Delete the sentence
Perform a blank determination.
AND
Line 13 of Analysis: Change
Result = [(VB… Read More
MICROCRYSTALLINE CELLULOSE IDENTIFICATION/B. Procedure USP35–NF30 1746 1-Oct-2012 USP37–NF32 First Supplement to USP36–NF31 4th formula of Analysis: Change
Result = (95) × [η]c/WS × [(100 − %LOD)/100]
to:
Result = [(95) × [η]c]/{WS × [(100 − %LOD)/100]}
MAGNESIUM STEARATE IMPURITIES/Chloride and Sulfate, Sulfate <221> USP35–NF30 1847 1-Oct-2012 USP37–NF32 First Supplement to USP36–NF31 Line 3: Change
0.020 N sulfuric acid (1.0%)
to:
0.020 M sulfuric acid (1.0%)
METHYL ALCOHOL ASSAY/Procedure USP35–NF30 1865 1-Oct-2012 USP37–NF32 First Supplement to USP36–NF31 Line 9 of System suitability: Change
Tailing factor: NLT 1.5 for methyl alcohol, System suitability solution
to:
Tailing factor: NMT 1.5 for methyl alcohol, System suitability solution
POLYETHYLENE OXIDE IMPURITIES/Organic Impurities/Procedure: Limit of Free Ethylene Oxide USP35–NF30 1906 1-Oct-2012 USP37–NF32 First Supplement to USP36–NF31 Line 2 of System suitability: Change
Samples: Standard stock solution and Standard solution C
to:
Sample: Standard solution C
<621> CHROMATOGRAPHY SYSTEM SUITABILITY/Stationary Phase USP35–NF30 258 1-Feb-2013 USP37–NF32 Second Supplement to USP36–NF31 Line 3 of Flow Rate (HPLC): Change
Read More
POLYSORBATE 20 SPECIFIC TESTS/Acid Value USP35–NF30 1919 1-Oct-2012 USP37–NF32 First Supplement to USP36–NF31 Line 1 of Sample: Change
10.0
to:
10.0 g
<1050> VIRAL SAFETY EVALUATION OF BIOTECHNOLOGY PRODUCTS DERIVED FROM CELL LINES OF HUMAN OR ANIMAL ORIGIN VI. Evaluation and Characterization of Viral Clearance Procedures USP35–NF30 553 1-Feb-2013 USP37–NF32 Second Supplement to USP36–NF31 Row 10 (Reovirus 3) of Column 5 (Genome) of Table A-1: Change
DNA
to:
RNA
POLYSORBATE 60 SPECIFIC TESTS/Acid Value USP35–NF30 1920 1-Oct-2012 USP37–NF32 First Supplement to USP36–NF31 Line 1 of Sample: Change
10.0
to:
10.0 g
ACESULFAME POTASSIUM IMPURITIES/Limit of Fluoride USP35–NF30 1680 1-Feb-2013 USP37–NF32 Second Supplement to USP36–NF31 Line 25 of Analysis: Change
C = concentration of fluoride in the Sample solution, from the standard curve (mg/mL)
to:
C = concentration of fluoride in the Sample solution, from the standard curve (µg/mL)
SODIUM HYDROXIDE ASSAY/Procedure USP35–NF30 1955 1-Oct-2012 USP37–NF32 First Supplement to USP36–NF31 Line 10 of Analysis: Change
Result = {[(VS1VB) × N × F1]/W} × 100
to:
Result = {[(VS2VB) × N × F1]/W} × 100
AND
Line 11 of Read More
CALCIUM SULFATE SPECIFIC TESTS/Loss on Drying <731> USP35–NF30 1724 1-Apr-2013 USP37–NF32 USP37–NF32 Line 1 of Acceptance criteria: Change
NMT 1.5% for the anhydrous form and NMT 19.0%–23.0% for the dihydrate
to:
NMT 1.5% for the anhydrous form and 19.0%–23.0% for the dihydrate
<81> Antibiotics—Microbial Assays Turbidimetric Method USP35–NF30 74 1-Dec-2012 USP37–NF32 Second Supplement to USP36–NF31 Line 8 of Analysis: Change
Include in each rack 1–2 control tubes containing 1 mL of the inoculum medium (see Table 8) but no antibiotic.
to:
Include in each rack 1–2 control tubes containing 1 mL of the test diluent (see Table 7) but no antibiotic.
GLYCERYL BEHENATE IMPURITIES USP35–NF30 1811 1-Feb-2013 USP37–NF32 Second Supplement to USP36–NF31 Line 34 of Content of 1-Monoglycerides/Analysis: Change
F = equivalency factor of glyceryl monobehenate, 207.3 mg/mEq
to:
F = equivalency factor of glyceryl monobehenate, 0.2073 g/mEq
AND
Line 19 of Limit of Free Glycerin/Analysis: Change
Read More
TREHALOSE ADDITIONAL REQUIREMENTS/USP Reference Standards <11> USP35–NF30 2007 1-Oct-2012 USP37–NF32 First Supplement to USP36–NF31 Line 2: Delete
USP Glycerin RS
IFOSFAMIDE Chloroform-insoluble phosphorus USP35–NF30 3477 1-Apr-2013 USP37–NF32 USP37–NF32 Line 18 of Test preparation: Change
ammonium hydroxide solution.
to:
ammonium hydroxide.
Polysorbate 80 SPECIFIC TESTS/Fats and Fixed Oils, Hydroxyl Value <401> USP35–NF30 1920 1-Dec-2012 USP37–NF32 Second Supplement to USP36–NF31 Line 13 of Analysis: Change
0.5 N alcoholic potassium hydroxide
to:
0.5 N alcoholic potassium hydroxide VS
GLYCERYL MONOOLEATE SPECIFIC TESTS/Fats and Fixed Oils, Fatty Acid Composition <401> USP35–NF30 1814 1-Feb-2013 USP37–NF32 Second Supplement to USP36–NF31 Column 3 of Table 1: Change in Row 1
Percentage, NMT (%)
to:
Percentage (%)
Change in Row 2
12.0
to:
NMT 12.0
Change in Row 3
6.0
to:
NMT 6.0
Change in Row 4
60.0
to:
NLT 60.0
Change in Row 5
35.0
to:
NMT 35.0
Change in Row 6
2.… Read More
THIMEROSAL TOPICAL AEROSOL SPECIFIC TESTS/Alcohol Determination, Method II <611> USP36–NF31 5369 1-Jun-2013 USP37–NF32 USP37–NF32 Line 4 of Analysis: Change
Determine the alcohol content of the sample thus prepared by the Gas–Liquid Chromatographic Method (see Method II in Alcohol Determination <611>, using methyl ethyl ketone as the internal standard in place of acetone.
to:
Read More
ONDANSETRON ORAL SOLUTION Related compounds USP36–NF31 4586 1-Apr-2014 USP38–NF33 USP38–NF33 Line 7 of Procedure: Change
(293.36/329.82)10,000(1 / F)(1 / V)(CS / CA)(ri / rS)
to:
(293.36 / 329.83)10,000(1 / F)(1 / V)(CS / CA)(ri… Read More
OLMESARTAN MEDOXOMIL IMPURITIES/Organic Impurities/Impurity Table USP36–NF31 4570 1-Aug-2013 USP38–NF33 First Supplement to USP37–NF32 Footnote d: Change
((5-Methyl-2-oxo-1,3-dioxol-4-yl)methyl 4-(2-hydroxypropan-2-yl)-2-propyl-1-((2´-(1-trityl-1H-tetrazol-5-yl)biphenyl-4-yl)methyl)-1H-imidazole-5-carboxylate.
to:
(5-Methyl-2-oxo-1,3-dioxol-4-yl)methyl 4-(2-hydroxypropan-2-yl)-2-propyl-1-((2´-(2-trityl-1… Read More
POTASSIUM METAPHOSPHATE SPECIFIC TESTS/Viscosity—Capillary Viscometer Methods <911> and Rotational Rheometer Methods <912> USP36–NF31 2172 1-Oct-2013 USP38–NF33 First Supplement to USP37–NF32 Line 1: Change
and
to:
or
TROLAMINE SALICYLATE Assay USP36–NF31 5499 1-Jun-2013 USP37–NF32 USP37–NF32 Line 3 of Chromatographic system: Change
L1
to:
L7
ONDANSETRON ORAL SOLUTION Assay USP36–NF31 4586 1-Apr-2014 USP38–NF33 USP38–NF33 Line 7 of Procedure: Change
(293.36/329.82)100(C/V)(rU / rS)
to:
(293.36 / 329.83)100(C / V)(rU / rS)
AND
Line 8 of Procedure: Change
329.82
to:
329.83
TRAMADOL HYDROCHLORIDE EXTENDED-RELEASE TABLETS IMPURITIES/Organic Impurities/Table 2 USP36–NF31 5438 1-Aug-2013 USP38–NF33 First Supplement to USP37–NF32 Footnote c: Change
1-(3-Methoxyphenyl)-2-(dimethylaminomethyl) cyclohex-1-ene hydrochloride (identified and reported as an individual unspecified impurity if present).
to:
1-(3-Methoxyphenyl)-2-(dimethylaminomethyl) cyclohex-6-ene hydrochloride (identified and reported as an individual… Read More
SORBITAN MONOLAURATE IDENTIFICATION/A. USP36–NF31 2212 1-Oct-2013 USP38–NF33 First Supplement to USP37–NF32 Line 1 of Sample: Change
1 g of the residue obtained in the Assay for Fatty Acids
to:
Residue obtained in the Assay for Fatty Acids
AND
Line 2 of Acceptance criteria: Change
260–280
to:
260–280 on 1-g sample
<228> ETHYLENE OXIDE AND DIOXANE Method II USP36–NF31 148 1-Jun-2013 USP37–NF32 USP37–NF32 Line 31 of Analysis: Change
rS = ethylene oxide peak responses from Standard solution B
to:
rS = dioxane peak responses from Standard solution B
VERAPAMIL HYDROCHLORIDE ORAL SOLUTION Assay USP36–NF31 5558 1-Jun-2013 USP37–NF32 USP37–NF32 Line 3 of Sodium acetate solution: Change
0.01 M
to:
0.01 N
AND
Line 6 of Assay preparation: Change
10-mL
to:
100-mL
SODIUM ACETATE IMPURITIES/Inorganic Impurities/Potassium USP36–NF31 5147 1-Apr-2014 USP38–NF33 USP38–NF33 Line 1 of Sample solution: Change
Equivalent to 600 mg/mL of anhydrous sodium acetate
to:
Dissolve the equivalent of 3 g of anhydrous sodium acetate in 5 mL of water.
AND
Line 1 of Analysis: Change
To 5 mL of Sample solution add
to:
To the Sample… Read More
VENLAFAXINE HYDROCHLORIDE ADDITIONAL REQUIREMENTS/USP Reference Standards <11> USP36–NF31 5551 1-Aug-2013 USP38–NF33 First Supplement to USP37–NF32 Line 2 of Venlafaxine Related Compound A RS: Change
1-(1-(4-methoxyphenyl)-2-(methylamino)ethyl)cyclohexanol.
C16H25NO2
263.38
to:
1-(1-(4-Methoxyphenyl)-2-(methylamino)ethyl)cyclohexanol hydrochloride.
C16H25NO2… Read More
SORBITAN MONOOLEATE IDENTIFICATION/A. USP36–NF31 2213 1-Oct-2013 USP38–NF33 First Supplement to USP37–NF32 Line 1 of Sample: Change
1 g of the residue obtained in the Assay for Fatty Acids
to:
Residue obtained in the Assay for Fatty Acids
AND
Line 2 of Acceptance criteria: Change
192–204
to:
192–204 on 1-g sample
<1052> BIOTECHNOLOGY-DERIVED ARTICLES—AMINO ACID ANALYSIS METHODOLOGIES OF AMINO ACID ANALYSIS GENERAL PRINCIPLES USP36–NF31 619 1-Jun-2013 USP37–NF32 USP37–NF32 Change the section title
Method 6—Postcolumn DABS-CI Derivatization General Principle
to:
Method 6—Precolumn DABS-CI Derivatization General Principle
THALIDOMIDE CAPSULES Dissolution <711> USP36–NF31 5347 1-Apr-2014 USP38–NF33 USP38–NF33 After the Test solution section: Add
to:
Chromatographic system—Prepare as directed in the Assay under Thalidomide.
VENLAFAXINE TABLETS ADDITIONAL REQUIREMENTS/USP Reference Standards <11> USP36–NF31 5554 1-Aug-2013 USP38–NF33 First Supplement to USP37–NF32 Line 2 of Venlafaxine Related Compound A RS: Change
1-(1-(4-methoxyphenyl)-2-(methylamino)ethyl)cyclohexanol.
C16H25NO2
263.38
to:
1-(1-(4-Methoxyphenyl)-2-(methylamino)ethyl)cyclohexanol hydrochloride.
C16H25NO2… Read More
SORBITAN MONOPALMITATE IDENTIFICATION/A. USP36–NF31 2213 1-Oct-2013 USP38–NF33 First Supplement to USP37–NF32 Line 1 of Sample: Change
1 g of the residue obtained in the Assay for Fatty Acids
to:
Residue obtained in the Assay for Fatty Acids
AND
Line 2 of Acceptance criteria: Change
210–225
to:
210–225 on 1-g sample
<1052> BIOTECHNOLOGY-DERIVED ARTICLES—AMINO ACID ANALYSIS APPENDIX USP36–NF31 619 1-Jun-2013 USP37–NF32 USP37–NF32 Change the section title
Method 6—Postcolumn DABS-CI Derivatization
to:
Method 6—Precolumn DABS-CI Derivatization
THIMEROSAL IMPURITIES/Mercury Ions USP36–NF31 5368 1-Apr-2014 USP38–NF33 USP38–NF33 Line 19 of Analysis:
CS = concentration of mercuric chloride in the Standard solution (mg/mL)
to:
CS = concentration of mercuric chloride in Sample solution B (mg/mL)
VERAPAMIL HYDROCHLORIDE ORAL SUSPENSION Assay USP36–NF31 5558 1-Jun-2013 USP37–NF32 USP37–NF32 Line 2 of Mobile phase: Change
0.01 M
to:
0.01 N
AND
Line 7 of Assay preparation: Change
10-mL
to:
100-mL
SORBITAN MONOSTEARATE IDENTIFICATION/A. USP36–NF31 2214 1-Oct-2013 USP38–NF33 First Supplement to USP37–NF32 Line 1 of Sample: Change
1 g of the residue obtained in the Assay for Fatty Acids
to:
Residue obtained in the Assay for Fatty Acids
AND
Line 2 of Acceptance criteria: Change
200–215
to:
200–215 on 1-g sample
CARAWAY OIL DEFINITION USP36–NF31 1924 1-Jun-2013 USP37–NF32 USP37–NF32 Line 3: Change
It contains NMT 50.0% of d-carvone (C10H14O).
to:
It contains NLT 50.0% of d-carvone (C10H14O).
GLYCERYL TRISTEARATE IDENTIFICATION/Fatty Acid Composition USP36–NF31 2033 1-Feb-2014 USP38–NF33 Second Supplement to USP37–NF32 Line 19 of Analysis: Change
Result = [(FMC × PFA1 × AMC)/(PMC × AFA1)] × 100
to:
Result = (FMC × PFA1 ×… Read More
VITAMIN E SPECIFIC TESTS/Acidity USP36–NF31 5579 1-Jun-2013 USP37–NF32 USP37–NF32 Line 1 of Sample: Change
40 mg
to:
1.0 g
SORBITAN SESQUIOLEATE IDENTIFICATION/A. USP36–NF31 2215 1-Oct-2013 USP38–NF33 First Supplement to USP37–NF32 Line 1 of Sample: Change
1 g of the residue obtained in the Assay for Fatty Acids
to:
Residue obtained in the Assay for Fatty Acids
AND
Line 2 of Acceptance criteria: Change
192–204
to:
192–204 on 1-g sample
NITRIC ACID ASSAY/Procedure USP36–NF31 2107 1-Jun-2013 USP37–NF32 USP37–NF32 Line 1 of Sample solution: Change
To 2 mL of Nitric Acid in a tared, glass-stoppered conical flask add 25 mL of water.
to:
Weigh 2 mL of Nitric Acid in a glass-stoppered conical flask, and add 25 mL of water.
ANAGRELIDE HYDROCHLORIDE ASSAY/Procedure/Chromatographic system/System suitability USP36–NF31 2500 1-Feb-2014 USP38–NF33 Second Supplement to USP37–NF32 Line 2 of Suitability requirements: Change
Column efficiency: NMT
to:
Column efficiency: NLT
SORBITAN TRIOLEATE IDENTIFICATION/A. USP36–NF31 2216 1-Oct-2013 USP38–NF33 First Supplement to USP37–NF32 Line 1 of Sample: Change
1 g of the residue of oleic acid obtained in the Assay for Fatty Acids
to:
Residue obtained in the Assay for Fatty Acids
AND
Line 2 of Acceptance criteria: Change
192–204
to:
192–204 on 1-g sample
STINGING NETTLE COMPOSITION/Content of Total Amino Acids USP36–NF31 1604 1-Aug-2013 USP38–NF33 First Supplement to USP37–NF32 Line 1 of Reagent solution: Change
Solution containing 1.00 g of ninhydrin, 1.50 g of hydrindantin,
to:
Solution containing 1.00 g of ninhydrin, 150 mg of hydrindantin,
STEAROYL POLYOXYLGLYCERIDES IMPURITIES/Limit of Free Glycerol USP36–NF31 2250 1-Oct-2013 USP38–NF33 First Supplement to USP37–NF32 Line 11 of Analysis: Change
(VSVB)
to:
(VBVS)
AND
Line 12 of Analysis: Change
VS = Titrant volume consumed by the Sample… Read More
BOSWELLIA SERRATA COMPOSITION/Content of Keto-Derivatives of β-Boswellic Acids/System suitability/Suitability requirements USP36–NF31 1366 1-Dec-2013 USP38–NF33 Second Supplement to USP37–NF32 Line 1 of Tailing factor: Change
11-keto-β-boswellic acid peak
to:
3-acetyl-11-keto-β-boswellic acid peak
ALBUTEROL SULFATE Chromatographic purity USP36–NF31 2352 1-Jun-2013 USP37–NF32 USP37–NF32 Line 1: Change
It meets the requirements of the test for Chromatographic purity under Albuterol, except to read Albuterol Sulfate in place of Albuterol and to use water instead of methanol as the solvent to prepare the Standard solution and the Test solution.
to… Read More